financetom
Business
financetom
/
Business
/
Capital One Roll-Off Will Soften Mastercard's Volume Growth Into 2026, Analyst Warns
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Capital One Roll-Off Will Soften Mastercard's Volume Growth Into 2026, Analyst Warns
Oct 31, 2025 10:43 AM

Mastercard Incorporated ( MA ) posted another strong quarter, fueled by resilient consumer spending and steady global transaction growth.

The results underscored the company’s ability to navigate currency shifts and competitive headwinds, even as portfolio conversions briefly tempered U.S. volumes in October.

JP Morgan analyst Tien-tsin Huang reiterated an Overweight rating on Mastercard ( MA ), with a price forecast of $685 after the company reported third-quarter fiscal 2025 results.

Earnings Results

The company reported quarterly net revenues of $8.60 billion, up 17% year-over-year and 15% Y/Y on a neutral currency basis, beating the analyst consensus estimate of $8.53 billion.

Mastercard ( MA ) expects net revenue growth in the high teens for the fourth quarter, versus the $8.71 billion analyst consensus estimate.

Mastercard ( MA ) expressed confidence in the broader economy, pointing to stable inflation, strong labor markets, and near-record financial markets that are boosting consumer wealth and spending.

The company continues to see solid consumer and business spending across both affluent and mass-market segments worldwide.

Also Read: Mastercard In ‘Late-Stage Talks’ To Acquire Crypto Startup Zerohash: Report

Analyst View

The analyst writes that Mastercard ( MA ) delivered solid results, with organic revenue growth surpassing expectations on stable U.S., international, and cross-border volumes.

The analyst says that management maintained a ‘consistent tone’ on the macro environment, noting steady spending trends into October.

Huang said the Capital One conversion slowed October’s U.S. volumes by about three points, an impact investors hadn’t fully anticipated, as the conversion effects appeared earlier and more sharply than expected.

Management says fiscal 2026 revenue will see modest pressure from the roll-off, partially offset by contractual obligations that taper in fiscal 2027, spreading the overall topline effect across years, says the analyst.

Huang now assumes the Capital One debit portfolio, which contributes over $110 billion in debit volume, will roll off by early 2026 (slightly slower than previously estimated), leading to a year-over-year softness in domestic volume growth.

Revised Estimates

Huang raised the fourth-quarter organic growth forecast slightly, reflecting stronger cross-border volume expectations.

For fiscal 2026, the analyst continues to forecast 11% organic revenue growth and 16% EPS growth.

The EPS estimates are now $4.21 for the fourth quarter (up from $4.17), $19.08 for fiscal 2026 (up from $19.05), and $21.88 for fiscal 2027 (up from $21.87), writes the analyst.

Price Action: MA shares were trading lower by 0.62% to $550.24 at last check Friday.

Read Next:

Deal Dispatch: Big Retailers Wreak Halloween Havoc On Sugar Land Candy Company

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Moderna Shares Fall After Cutting Annual R&D Spending by $1.1 Billion From 2027
Update: Moderna Shares Fall After Cutting Annual R&D Spending by $1.1 Billion From 2027
Sep 13, 2024
11:09 AM EDT, 09/12/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and the first paragraph.) Moderna ( MRNA ) shares fell more than 18% in recent Thursday trading after the company said it is reducing its annual R&D expense by about $1.1 billion starting in 2027 in light of recent commercial challenges. The company now...
--Street Color: US FDA Authorizes Over-the-Counter Hearing Aid Software for Apple's AirPods Pro
--Street Color: US FDA Authorizes Over-the-Counter Hearing Aid Software for Apple's AirPods Pro
Sep 13, 2024
11:09 AM EDT, 09/12/2024 (MT Newswires) -- Price: 222.76, Change: +0.10, Percent Change: +0.04 ...
Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing
Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing
Sep 13, 2024
11:08 AM EDT, 09/12/2024 (MT Newswires) -- Dennis H Nelson, Director, President & CEO, on September 10, 2024, sold 20,453 shares in Buckle (BKE) for $854,496. Following the Form 4 filing with the SEC, Nelson has control over a total of 2,310,552 shares of the company, with 324,000 shares held directly and 1,986,552 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/885245/000088524524000087/xslF345X05/wk-form4_1726153070.xml Price: 41.56,...
Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall
Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall
Sep 13, 2024
11:13 AM EDT, 09/12/2024 (MT Newswires) -- Oncternal Therapeutics' ( ONCT ) shares sank 58% in recent Thursday trading after the company said it has decided to discontinue its clinical studies and explore strategic alternatives. The company also said it will discontinue all product development activities, lay off some staff, and implement other cost-cutting measures while exploring alternatives, which may...
Copyright 2023-2026 - www.financetom.com All Rights Reserved